PubMed Health⌕ Search

Biomedical subjects

P Meoli

Publications and source records attributed to P Meoli.

9 recordsLinked to original sources
PubMed2006

A modified simulated annealing algorithm for parameter determination for a hybrid virtual model.

In this work we present an algorithm based on the simulated annealing (SA) method for electron beam spectrum reconstruction from central axis PDD data. We use a simulated beam in order to assess the accuracy of the method, and compare it with others usually employed. We found that our modified SA algorithm produced excellent reconstructed PDDs and beam profiles and improved reconstructed spectra. We also tested our method for the simultaneous determination of an electron energy spectrum and the position of a trimmer from central axis PDD data, and found this to be sufficient for the determination of the physical parameters of this hybrid model.

Algorithms↗
PubMed1987

[Role of Holter electrocardiogram in the evaluation of anti-arrhythmia therapy].

Statistical models may be useful in order to evaluate antiarrhythmic treatment and to distinguish between drug efficacy and spontaneous variability of premature ventricular depolarizations. Analysis of variance and linear regression analysis have been both proposed for documenting antiarrhythmic efficacy. Holter/exercise approach has been designed as noninvasive method of drug testing. So far only one group has reported the long-term outcome of patients managed using this approach. Patients with malignant ventricular arrhythmias in which efficacy was achieved had better chance of surviving during follow-up than did the nonresponder patients. In addition to acute drug testing, chronic trials have been undertaken. One group has reported the long-term results in 124 drug trials and the efficacy was controlled by Holter monitoring. Cumulative probability of survival at 24 months was better for responders than for nonresponders (P less than 0.001). Perspective trials with antiarrhythmic drug are being concluded, such as CAPS and TEST. The results are imminent. Additional aspects to be considered are that critical suppression of premature ventricular depolarizations by Holter does not predict long-term remission of malignant ventricular arrhythmias. Comparison of follow-up results by programmed electrical stimulation and by Holter monitoring are not similar; retrospective non randomized studies show that programmed stimulation was superior to ambulatory monitoring in predicting drug efficacy, or that clinical outcome in patients whose regimen had been found ineffective by programmed stimulation, was as good as the outcome in patients effectively controlled by Holter monitoring.(ABSTRACT TRUNCATED AT 250 WORDS)

Analysis of Variance↗
PubMed1983

Antiarrhythmic effectiveness of propafenone compared to lorajmine in ventricular arrhythmias. Controlled clinical trial.

A randomized double-blind cross-over trial was carried out in 20 patients suffering from ventricular ectopic contractions (VECs), in order to evaluate the effectiveness of a new antiarrhythmic drug, Propafenone (P), versus Lorajmine (L). The patients were given 900 mg/day P and 600 mg/day L in three divided doses for 3 days. Every patient was evaluated with four 24-hour ambulatory ECGs, the first at the beginning of the trial, the second after the administration of the first drug, the third after the administration of the second drug and the last after wash-out. With P, the average fall in VECs was 70.6 +/- 10.8% with a clinically significant individual response in 14 of the 20 patients (VECs reduction greater than or equal to 75%, VECs mean decrease: 93.5 +/- 2.1%). With L, VECs decreased by 37.4 +/- 14.2% whilst VECs reduction was larger than 75% only in 50% patients (VECs mean decrease 85.8 +/- 3.1%). Lastly, after therapy interruption, VECs globally increased by +5.4 +/- 14.4%. Propafenone is a considerably active drug against ventricular arrhythmias. It proved to be more effective than Lorajmine under our experimental conditions.

Adolescent↗
PubMed1982

[Clinical study evaluated by Holter monitoring and by mexiletine serum levels in ventricular arrhythmias].

Three normal individuals and 17 cardiac patients with frequent VPBs were given mexiletine orally for 5 days (400-1000 mg daily in two to five doses). Each patient was evaluated by means of 24-hour Holter monitoring before treatment, on the fifth day and 4 days after the drug was discontinued. In 15 patients mexiletine serum levels were measured before and 2 hours after the first dose given in the morning. Urinary pH was also measured. VPBs were reduced by an average of 67.6%; in 11 patients the VPBs decreased by 92.3%. After treatment was discontinued, VPBs increased by 2.6%. Serum levels of the drug were generally within the therapeutic range (1.05 +/- 0.39 mcg/ml). We conclude that mexiletine is effective in reducing the number of VPBs; Holter monitoring and serum level measurements are both clinically helpful.

Administration, Oral↗